BioSyent Inc.
RX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.99M | 10.00M | 6.94M | 8.87M | 7.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.99M | 10.00M | 6.94M | 8.87M | 7.36M |
| Cost of Revenue | 4.16M | 2.69M | 1.60M | 2.15M | 1.64M |
| Gross Profit | 9.84M | 7.31M | 5.34M | 6.73M | 5.72M |
| SG&A Expenses | 6.21M | 4.48M | 3.75M | 4.24M | 3.68M |
| Depreciation & Amortization | 738.70K | 351.60K | -- | -- | 153.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.11M | 7.52M | 5.34M | 6.38M | 5.50M |
| Operating Income | 2.88M | 2.48M | 1.60M | 2.49M | 1.86M |
| Income Before Tax | 2.80M | 2.36M | 1.78M | 2.65M | 1.98M |
| Income Tax Expenses | 789.10K | 676.30K | 349.00K | 702.20K | 525.90K |
| Earnings from Continuing Operations | 2.01M | 1.69M | 1.43M | 1.95M | 1.46M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.01M | 1.69M | 1.43M | 1.95M | 1.46M |
| EBIT | 2.88M | 2.48M | 1.60M | 2.49M | 1.86M |
| EBITDA | 3.56M | 2.79M | 1.73M | 2.65M | 2.01M |
| EPS Basic | 0.18 | 0.15 | 0.13 | 0.17 | 0.13 |
| Normalized Basic EPS | 0.16 | 0.14 | 0.10 | 0.15 | 0.11 |
| EPS Diluted | 0.17 | 0.15 | 0.12 | 0.17 | 0.13 |
| Normalized Diluted EPS | 0.16 | 0.14 | 0.10 | 0.14 | 0.11 |
| Average Basic Shares Outstanding | 11.39M | 11.34M | 11.26M | 11.26M | 11.25M |
| Average Diluted Shares Outstanding | 11.63M | 11.60M | 11.51M | 11.50M | 11.50M |
| Dividend Per Share | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Payout Ratio | 21.90% | 26.42% | 28.27% | 20.99% | 27.88% |